GuruFocus Premium Membership

Serving Intelligent Investors since 2004. Only 96 cents a day.

Free Trial

Free 7-day Trial
All Articles and Columns »

Will Pfizer’s Q1 2014 Earnings Beat the Street on May 5, 2014?

May 05, 2014 | About:
Karen Rogers

Karen Rogers

1 followers

Pfizer (PFE) will release its first quarter 2014 earnings report before the opening bell on Monday, May 5, 2014. Since the company has posted higher than expected earnings over the past three quarters, analysts and investors are looking for the pharmaceutical giant to beat the Street’s estimates once again.

Previous Quarterly Performances

Pfizer’s EPS has exceeded analyst predictions by an average of 4.31% over the past three quarters.

EPS

Q1 2014

Q4 2013

Q3 2013

Q2 2013

Estimate

$0.55

$0.52

$0.56

$0.55

Actual

 

$0.56

$0.58

$0.56

Revenue Growth Outlook

Pfizer’s revenue outlook is strong due to the growing sales of its current drug lines and the potential future profits found in the drugs currently moving through the development and testing stages. The company saw its profits increase due to the rising global demand for Lyrica, Celebrex and Xalkori, and increased U.S. demand for Xeljanz and Eliquis.

Pfizer currently has several drugs in its pipeline that recently received approval from the U.S. Food and Drug Administration: cancer drug Xalkori, menopause treatment drug Duavee and pain medication Embeda. Pfizer also has several drugs working through the testing phase including breast cancer treatment drug Palbociclib, heart drug Tafamidis and cholesterol drug Bococizumab. Both Pfizer and Merck (MRK) are currently collaborating to develop Type II diabetes drug Ertugliflozin. Pfizer is also collaborating with Eli Lilly (LLY) to develop pain medication Tanezumab.

Negative Revenue Factors

Pfizer saw a sharp decline in product revenue when the patent expired for cholesterol lowering drug Lipitor on Nov. 30, 2011 and the collaboration agreement for arthritis drug Enbrel expired on Oct. 31, 2013. The company will experience further revenue declines as drug patents expire in the future. In addition, unfavorable interest rates and currency exchange rates continue to negatively impact Pfizer’s profits.

Analysts Expectations

Analysts are looking for Pfizer to beat the Street’s estimates for the fourth consecutive quarter. The EPS estimates range from a low of $0.52 to a high of $0.59 with the target EPS pegged at $0.55. The estimated revenue ranges from a low of $11.8 billion to a high of $12.2 billion with a target of $12 billion. However, hitting the $12 billion target mark means that the company’s first quarter 2014 revenue declined by 11% when compared to the $13.5 billion quarterly revenue reported in fourth quarter 2013.

Revenue

Q1 2014

Q4 2013

Q3 2013

Q2 2013

Estimate

$12B

$13.4B

$12.7B

$13B

Actual

 

$13.5B

$12.6B

$13B

Trading the Earnings Report

On a scale of 0 to 10, analysts currently rate Pfizer as a hold at 5.4. Analysts at Thompson Reuters rate the stock as a buy while Zack’s Investment Research rates Pfizer as a hold. The stock price has bounced between $29.58 and $32.35 since April 14, 2014. Due to Pfizer’s current revenue growth and future income potential, taking a long position should be considered a long-term investment. Using Pfizer’s stock price of $30.79 as the pivot point, support and resistance can be pegged at these levels:

 

Support

 

Resistance

S1

$30.51

R1

$31.02

S2

$30.28

R2

$31.30

S3

$30.00

R3

$31.53

Analysts’ long-term stock target price is $38.00 a share.

Disclosure: I do not own stock in any of the companies included in this article and have no intention of opening a position in the next 72 hours.


Rating: 0.0/5 (0 votes)

Comments

Please leave your comment:


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide